Brookline analyst Kemp Dolliver downgraded Biocept to Hold from Buy and suspended his price target on the shares after the company announced that it has commenced a process to explore and evaluate strategic alternatives.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIOC: